Differential expression of extracellular matrix‑related genes DCN, EPHA4, FN1, SPARC, SPON2 and SPP1 in colorectal carcinogenesis

  • Authors:
    • Margareta Žlajpah
    • Nina Hauptman
    • Emanuela Boštjančič
    • Nina Zidar
  • View Affiliations

  • Published online on: August 9, 2019     https://doi.org/10.3892/or.2019.7274
  • Pages: 1539-1548
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

During colorectal carcinogenesis, a spectrum of lesions is formed with different malignant potentials and occasionally with ambiguous morphologic features. To identify novel biomarkers, we previously performed a bioinformatics study to detect differentially expressed genes between colorectal adenoma (CRA) and colorectal carcinoma (CRC). The present study validated the diagnostic and prognostic significance of 6 components of the extracellular matrix (ECM) that were identified in the previous bioinformatics analysis [decorin (DCN), erythropoietin‑producing hepatoma receptor A4 (EPHA4), fibronectin 1 (FN1), secreted protein acidic and cysteine rich (SPARC), spondin 2 (SPON2) and secreted phosphoprotein 1 (SPP1)], by analyzing their gene and protein expression levels in all samples. A total of 60 formalin‑fixed paraffin‑embedded biopsy samples were included in the present study, from 40 patients with CRA, malignant polyps and CRC with and without lymph node metastases. The expression of the ECM‑related genes was evaluated on the mRNA level using reverse transcription‑quantitative PCR (RT‑qPCR) and on the protein level using immunohistochemistry. RT‑qPCR results revealed differential expression among the groups for all genes, except for EPHA4. Their expression proportionally increased with the level of malignancy. Among them, SPARC, SPON2 and SPP1 were differentially expressed between CRA and malignant polyps. Immunohistochemistry analysis revealed two patterns: Positive staining of SPON2 and SPP1 in epithelial cells of healthy mucosa and dysplastic glands of CRA and CRC, and positive staining of DCN and SPARC in the lamina propria in healthy mucosa and stroma of CRA and CRC. The intensity of staining increased with the severity of lesions. The present results suggested that ECM‑related proteins may have an important role in the development of CRC, with a possible diagnostic use for differentiation among various lesions, such as between CRA and malignant polyps. However, no significant potential was detected for these genes to predict lymph node metastases in CRC.

References

1 

Simon K: Colorectal cancer development and advances in screening. Clin Interv Aging. 11:967–976. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Mathonnet M, Perraud A, Christou N, Akil H, Melin C, Battu S, Jauberteau MO and Denizot Y: Hallmarks in colorectal cancer: Angiogenesis and cancer stem-like cells. World J Gastroenterol. 20:4189–4196. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T: Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI

4 

Shepherd NA and Griggs RK: Bowel cancer screening-generated diagnostic conundrum of the century: Pseudoinvasion in sigmoid colonic polyps. Mod Pathol. 1 (Suppl 28):S88–S94. 2015. View Article : Google Scholar

5 

Griggs RK, Novelli MR, Sanders DS, Warren BF, Williams GT, Quirke P and Shepherd NA: Challenging diagnostic issues in adenomatous polyps with epithelial misplacement in bowel cancer screening: 5 years' experience of the bowel cancer screening programme expert board. Histopathology. 70:466–472. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Panarelli NC, Somarathna T, Samowitz WS, Kornacki S, Sanders SA, Novelli MR, Shepherd NA and Yantiss RK: Diagnostic challenges caused by endoscopic biopsy of colonic polyps: A systematic evaluation of epithelial misplacement with review of problematic polyps from the bowel cancer screening program, United Kingdom. Am J Surg Pathol. 40:1075–1083. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Loughrey MB and Shepherd NA: The pathology of bowel cancer screening. Histopathology. 66:66–77. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Aghagolzadeh P and Radpour R: New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 22:5678–5693. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Hauptman N, Boštjančič E, Žlajpah M, Ranković B and Zidar N: Bioinformatics analysis reveals most prominent gene candidates to distinguish colorectal adenoma from adenocarcinoma. Biomed Res Int. 2018:94165152018. View Article : Google Scholar : PubMed/NCBI

10 

Lu P, Takai K, Weaver VM and Werb Z: Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 3:a0050582011. View Article : Google Scholar : PubMed/NCBI

11 

Lu P, Weaver VM and Werb Z: The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 196:395–406. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Venning FA, Wullkopf L and Erler JT: Targeting ECM disrupts cancer progression. Front Oncol. 5:2242015. View Article : Google Scholar : PubMed/NCBI

13 

Pickup MW, Mouw JK and Weaver VM: The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15:1243–1253. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Fang M, Yuan J, Peng C and Li Y: Collagen as a double-edged sword in tumor progression. Tumour Biol. 35:2871–2882. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Boudjadi S, Bernatchez G, Beaulieu JF and Carrier JC: Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am J Pathol. 183:266–276. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Imano M, Okuno K, Itoh T, Ishimaru E, Satou T and Shiozaki H: Increased osteopontin-positive macrophage expression in colorectal cancer stroma with synchronous liver metastasis. World J Surg. 34:1930–1936. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR and Janssen KP: Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 121:1717–1723. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Galamb O, Sipos F, Spisak S, Galamb B, Krenacs T, Valcz G, Tulassay Z and Molnar B: Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol. 31:19–29. 2009.PubMed/NCBI

19 

Valcz G, Sipos F, Krenacs T, Molnar J, Patai AV, Leiszter K, Toth K, Solymosi N, Galamb O, Molnar B and Tulassay Z: Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence. Pathol Oncol Res. 16:541–545. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Augoff K, Rabczynski J, Tabola R, Czapla L, Ratajczak K and Grabowski K: Immunohistochemical study of decorin expression in polyps and carcinomas of the colon. Med Sci Monit. 14:CR530–CR535. 2008.PubMed/NCBI

21 

Liu QZ, Gao XH, Chang WJ, Wang HT, Wang H, Cao GW and Fu CG: Secreted protein acidic and rich in cysteine expression in human colorectal cancer predicts postoperative prognosis. Eur Rev Med Pharmacol Sci. 19:1803–1811. 2015.PubMed/NCBI

22 

Nyman MC, Sainio AO, Pennanen MM, Lund RJ, Vuorikoski S, Sundström JT and Järveläinen HT: Decorin in human colon cancer: Localization in vivo and effect on cancer cell behavior in vitro. J Histochem Cytochem. 63:710–720. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Cai X, Liu C, Zhang TN, Zhu YW, Dong X and Xue P: Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J Cell Biochem. 119:4717–4728. 2018. View Article : Google Scholar : PubMed/NCBI

24 

Thorsen SB, Lundberg M, Villablanca A, Christensen SL, Belling KC, Nielsen BS, Knowles M, Gee N, Nielsen HJ, Brunner N, et al: Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med. 11:2532013. View Article : Google Scholar : PubMed/NCBI

25 

Wang S, Zhang C, Zhang Z, Qian W and Sun Y, Ji B, Zhang Y, Zhu C, Ji D, Wang Q and Sun Y: Transcriptome analysis in primary colorectal cancer tissues from patients with and without liver metastases using next-generation sequencing. Cancer Med. 6:1976–1987. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Zhang Q, Wang XQ, Wang J, Cui SJ, Lou XM, Yan B, Qiao J, Jiang YH, Zhang LJ, Yang PY and Liu F: Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. Oncotarget. 6:15095–15110. 2015.PubMed/NCBI

27 

Zhao M, Liang F, Zhang B, Yan W and Zhang J: The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: A systematic meta-analysis. Sci Rep. 5:127132015. View Article : Google Scholar : PubMed/NCBI

28 

Sethi MK, Thaysen-Andersen M, Kim H, Park CK, Baker MS, Packer NH, Paik YK, Hancock WS and Fanayan S: Quantitative proteomic analysis of paired colorectal cancer and non-tumorigenic tissues reveals signature proteins and perturbed pathways involved in CRC progression and metastasis. J Proteomics. 126:54–67. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Oshima T, Akaike M, Yoshihara K, Shiozawa M, Yamamoto N, Sato T, Akihito N, Nagano Y, Fujii S, Kunisaki C, et al: Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer. Int J Oncol. 33:573–577. 2008.PubMed/NCBI

30 

Adany R and Iozzo RV: Hypomethylation of the decorin proteoglycan gene in human colon cancer. Biochem J. 276:301–306. 1991. View Article : Google Scholar : PubMed/NCBI

31 

Tang RY, Wang Z, Chen HQ and Zhu SB: Negative correlation between miR-200c and decorin plays an important role in the pathogenesis of colorectal carcinoma. Biomed Res Int. 2017:10389842017. View Article : Google Scholar : PubMed/NCBI

32 

Liang JF, Wang HK, Xiao H, Li N, Cheng CX, Zhao YZ, Ma YB, Gao JZ, Bai RB and Zheng HX: Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res. 29:712010. View Article : Google Scholar : PubMed/NCBI

33 

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weissenbacher B, Lax S, Gnant M, Wrba F, Greil R, et al: Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Mod Pathol. 27:906–915. 2014. View Article : Google Scholar : PubMed/NCBI

34 

Zhang S, Jin J, Tian X and Wu L: hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC. Oncotarget. 8:104508–104524. 2017.PubMed/NCBI

35 

Viana Lde S, Affonso RJ Jr, Silva SR, Denadai MV, Matos D, Salinas de Souza C and Waisberg J: Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. Oncology. 84:81–91. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Mlakar V, Berginc G, Volavsek M, Stor Z, Rems M and Glavac D: Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. BMC Cancer. 9:2822009. View Article : Google Scholar : PubMed/NCBI

37 

Chew A, Salama P, Robbshaw A, Klopcic B, Zeps N, Platell C and Lawrance IC: SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer. PLoS One. 6:e220472011. View Article : Google Scholar : PubMed/NCBI

38 

Choe EK, Yi JW, Chai YJ and Park KJ: Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancer. J Surg Oncol. 117:1833–1840. 2018. View Article : Google Scholar : PubMed/NCBI

39 

Archer. PreSeq™ RNA QC Assay. Tecnical note. simplehttps://archerdx.com/support/preseq-dnaJune 17–2019

40 

Latham GJ: Normalization of microRNA quantitative RT-PCR data in reduced scale experimental designs. Methods Mol Biol. 667:19–31. 2010. View Article : Google Scholar : PubMed/NCBI

41 

Goni R, Garcia P and Foissac S: The qPCR data statistical analysis. Integromics White Paper 2009. simplehttps://gene-quantification.de/integromics-qpcr-statistics-white-paper.pdfJune 17–2019

42 

Wei R, Wong JPC and Kwok HF: Osteopontin-a promising biomarker for cancer therapy. J Cancer. 8:2173–2183. 2017. View Article : Google Scholar : PubMed/NCBI

43 

Shevde LA and Samant RS: Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 37:131–141. 2014. View Article : Google Scholar : PubMed/NCBI

44 

Yang E, Kang HJ, Koh KH, Rhee H, Kim NK and Kim H: Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer. 121:567–575. 2007. View Article : Google Scholar : PubMed/NCBI

45 

Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D and Tai IT: SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer. 98:1810–1819. 2008. View Article : Google Scholar : PubMed/NCBI

46 

Tai IT and Tang MJ: SPARC in cancer biology: Its role in cancer progression and potential for therapy. Drug Resist Updat. 11:231–246. 2008. View Article : Google Scholar : PubMed/NCBI

47 

Vaz J, Ansari D, Sasor A and Andersson R: SPARC: A potential prognostic and therapeutic target in pancreatic cancer. Pancreas. 44:1024–1035. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Yuan X, Bian T, Liu J, Ke H, Feng J, Zhang Q, Qian L, Li X, Liu Y and Zhang J: Spondin2 is a new prognostic biomarker for lung adenocarcinoma. Oncotarget. 8:59324–59332. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Feng Y, Hu Y, Mao Q, Guo Y, Liu Y, Xue W and Cheng S: Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma. J Int Med Res. 47:569–579. 2019. View Article : Google Scholar : PubMed/NCBI

50 

Jin C, Lin JR, Ma L, Song Y, Shi YX, Jiang P, Dong Y and Li XS: Elevated spondin-2 expression correlates with progression and prognosis in gastric cancer. Oncotarget. 8:10416–10424. 2017.PubMed/NCBI

51 

Jarvinen TA and Prince S: Decorin: A growth factor antagonist for tumor growth inhibition. Biomed Res Int. 2015:6547652015. View Article : Google Scholar : PubMed/NCBI

52 

Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, Xiao F, Bai Z, Yao H, Ma X, et al: An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic dignals and via immune activation. Hum Gene Ther. 28:667–680. 2017. View Article : Google Scholar : PubMed/NCBI

53 

Yi W, Xiao E, Ding R, Luo P and Yang Y: High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer. Oncol Rep. 36:3145–3153. 2016. View Article : Google Scholar : PubMed/NCBI

54 

Kullander K and Klein R: Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 3:475–486. 2002. View Article : Google Scholar : PubMed/NCBI

55 

de Marcondes PG and Morgado-Diaz JA: The role of EphA4 signaling in radiation-induced EMT-like phenotype in colorectal cancer cells. J Cell Biochem. 118:442–445. 2017. View Article : Google Scholar : PubMed/NCBI

56 

Patel PG, Selvarajah S, Guerard KP, Bartlett JMS, Lapointe J, Berman DM, Okello JBA and Park PC: Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores. PLoS One. 12:e01797322017. View Article : Google Scholar : PubMed/NCBI

57 

von Ahlfen S, Missel A, Bendrat K and Schlumpberger M: Determinants of RNA quality from FFPE samples. PLoS One. 2:e12612007. View Article : Google Scholar : PubMed/NCBI

58 

Guerra JM, Monteiro RL, Gonzalez L, Kimura LM, Cirqueira CDS and de Araujo LJT: Against all odds: RNA extraction from different protocols adapted to formalin-fixed paraffin-embedded tissue. Appl Immunohistochem Mol Morphol. May 23–2019.(Epub ahead of print). doi: 10.1097/PAI.0000000000000772. View Article : Google Scholar : PubMed/NCBI

59 

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al: The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 42 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Žlajpah, M., Hauptman, N., Boštjančič, E., & Zidar, N. (2019). Differential expression of extracellular matrix‑related genes DCN, EPHA4, FN1, SPARC, SPON2 and SPP1 in colorectal carcinogenesis. Oncology Reports, 42, 1539-1548. https://doi.org/10.3892/or.2019.7274
MLA
Žlajpah, M., Hauptman, N., Boštjančič, E., Zidar, N."Differential expression of extracellular matrix‑related genes DCN, EPHA4, FN1, SPARC, SPON2 and SPP1 in colorectal carcinogenesis". Oncology Reports 42.4 (2019): 1539-1548.
Chicago
Žlajpah, M., Hauptman, N., Boštjančič, E., Zidar, N."Differential expression of extracellular matrix‑related genes DCN, EPHA4, FN1, SPARC, SPON2 and SPP1 in colorectal carcinogenesis". Oncology Reports 42, no. 4 (2019): 1539-1548. https://doi.org/10.3892/or.2019.7274